Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients who have had an unprovoked deep venous thrombosis (DVT) or pulmonary embolus (PE) are at a high risk for recurrent venous thromboembolism (VTE). Extended "life-long" anticoagulation has been recommended in these patients. However, the risk benefit ratio of this approach is controversial and the role of the direct oral anticoagulants (DOACs) and aspirin is unclear. Furthermore, in some patients with a "weak provoking factor" there is clinical equipoise regarding continuation or cessation of anticoagulant therapy after treatment of the acute VTE event. OBJECTIVE: A systematic review and meta-analysis to determine the risks (major bleeding) and benefits (recurrent VTE and mortality) of extended anticoagulation with vitamin k antagonists (VKA), DOACs and aspirin in patients with an unprovoked VTE and in those patients with clinical equipoise regarding continuation or cessation of anticoagulant therapy. In addition, we sought to determine the risk of recurrent VTE events once extended anti-thrombotic therapy was discontinued. DATA SOURCES: MEDLINE, Cochrane Register of Controlled Trials, citation review of relevant primary and review articles. STUDY SELECTION: Randomized placebo-controlled trials (RCTs) that compared the risk of recurrent VTE in patients with an unprovoked DVT or PE who had been treated for at least 3 months with a VKA or a DOAC and were then randomized to receive an oral anti-thrombotic agent or placebo for at least 6 additional months. We included studies that included patients in whom clinical equipoise existed regarding the continuation or cessation of anticoagulant therapy. DATA EXTRACTION: Independent extraction of articles by both authors using predefined data fields, including study quality indicators. Data were abstracted on study size, study setting, initial event (DVT or PE), percentage of patients where the initial VTE event was unprovoked, the number of recurrent VTE events, major bleeds and mortality during the period of extended anticoagulation in the active treatment and placebo arms. In addition, we recorded the event rate once extended treatment was stopped. Meta-analytic techniques were used to summarize the data. Studies were grouped according to the type of anti-thrombotic agent. DATA SYNTHESIS: Seven studies which enrolled 6778 patients met our inclusion criteria; two studies evaluated the extended use of Coumadin, three studies evaluated a DOAC and two studies evaluated the use of aspirin. The duration of followup varied from 6 to 37 months. In the Coumadin and aspirin studies 100% of the randomized patients had an unprovoked VTE, while in the DOAC studies between 73.5% and 93.2% of the VTE events were unprovoked. In the control group recurrent VTE occurred in 9.7% of patients compared to 2.8% in the active treatment group (OR 0.21; 95% CI 0.11-0.42, p<0.0001). VKA, DOACs and aspirin significantly reduced the risk of recurrent VTE, with VKA and DOACs being significantly more effective than aspirin. Major bleeding events occurred in 12 patients in the control group (0.4%) and 25 of 3815 (0.6%) patients in the active treatment group (OR 1.64; 95% CI 0.69-3.90, NS). There were 39 (1.3%) deaths in control patients and 33 (0.9%) deaths in the anti-thrombotic group during the treatment period (OR 0.73; 95% CI 0.40-1.33, NS). Patients whose initial VTE event was a PE were more likely to have a recurrent PE than a DVT. The annualized event rate after discontinuation of extended antithrombotic therapy was 4.4% in the control group and 6.5% in the active treatment arm. CONCLUSIONS: VKA, DOACs and aspirin significantly reduced the risk of recurrent VTE, with DOACs and VKA being more effective than aspirin. The decision regarding life-long anticoagulation following an unprovoked DVT or PE should depend on the patients' risk for recurrent PE as well as the patients' values and preferences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“We identified 19 systematic reviews 239-257 and 13 RCTs 88,258,259,261,262,265,267,298,306-310 (n 5 8593) to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [246]
The cited source says what the claim attributes to it.
In the citing paper
“However, a systematic review and metaanalysis comparing extended anticoagulant therapy and aspirin found that anticoagulant therapy was more effective than aspirin in preventing recurrent VTE, 246”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [246]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119 · cited 3×
“Current guidelines recommend three months of anticoagulation to complete treatment of the acute episode of VTE (provoked or unprovoked); this is known as the “active treatment” phase.[2,3] Recurrent VTE after discontinuation of Secondary Prevention of Idiopathic Thromboembolic Disease”
BackgroundMethodThe combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Investigating and dealing with publication and other biases in meta-analysis
Sterne, J. A. C., Egger, M., & Smith, G. D. (2001) · BMJ · doi:10.1136/bmj.323.7304.101 · Cited by 2,225
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Cited by
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Lyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Kakkos, S. K., Gohel, M., Baekgaard, N., Bauersachs, R., Bellmunt-Montoya, S., Black, S. A., ten Cate-Hoek, A. J., Elalamy, I., Enzmann, F. K., Geroulakos, G., et al. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2020.09.023 · Cited by 743
Therapeutic strategies for thrombosis: new targets and approaches
Mackman, N., Bergmeier, W., Stouffer, G. A., & Weitz, J. I. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0061-0 · Cited by 388
Venous Thromboembolism: Advances in Diagnosis and Treatment
Tritschler, T., Kraaijpoel, N., Le Gal, G., & Wells, P. S. (2018) · JAMA · doi:10.1001/jama.2018.14346 · Cited by 357
Lindström, S., Wang, L., Smith, E. N., Gordon, W., van Hylckama Vlieg, A., de Andrade, M., Brody, J. A., Pattee, J. W., Haessler, J., Brumpton, B. M., et al. (2019) · Blood · doi:10.1182/blood.2019000435 · Cited by 223
Twine, C. P., Kakkos, S. K., Aboyans, V., Baumgartner, I., Behrendt, C.-A., Bellmunt-Montoya, S., Jilma, B., Nordanstig, J., Saratzis, A., Reekers, J. A., et al. (2023) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.03.042 · Cited by 197
Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 128
Acute pulmonary embolism: a concise review of diagnosis and management
Rayner, M., Darvall, J. N., & Hammerschlag, G. (2019) · Internal Medicine Journal · doi:10.1111/imj.14145 · Cited by 120
Venous and Arterial Thromboses: Two Sides of the Same Coin?
Lippi, G., & Favaloro, E. J. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1607202 · Cited by 103
Becatti, M., Emmi, G., Bettiol, A., Silvestri, E., Scala, G. D., Taddei, N., Prisco, D., & Fiorillo, C. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13243 · Cited by 72
Cohen, A. T., Hamilton, M., Bird, A., Mitchell, S. A., Li, S., Horblyuk, R. V., & Batson, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160064 · Cited by 74
Wang, H., Wang, Q., Wang, J., Guo, C., Kleiman, K., Meng, H., Knight, J. S., & Eitzman, D. T. (2017) · Scientific Reports · doi:10.1038/s41598-017-14307-x · Cited by 51
Observational study of people infected with SARS-Cov-2, treated with amantadine
Aranda-Abreu, G. E., Aranda‐Martínez, J. D., Araújo, R., Hernández‐Aguilar, M. E., Herrera‐Covarrubias, D., & Rojas-Durán, F. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00168-1 · Cited by 42
Chang, E. I.-F., & Liu, J. (2018) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000004550 · Cited by 37
Weitz, J. I., Jaffer, I., & Fredenburgh, J. C. (2017) · F1000Research · doi:10.12688/f1000research.11174.1 · Cited by 40
Antiplatelet agents for the treatment of deep venous thrombosis
Flumignan, C. D. Q., Nakano, L. C. U., Baptista-Silva, J. C., & Flumignan, R. L. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012369.pub2 · Cited by 40
Weitz, J. I., & Jaffer, I. (2016) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3547 · Cited by 28
Seagrave, K. G., Fletcher, J., & Hitos, K. (2020) · International Angiology · doi:10.23736/s0392-9590.19.04086-0 · Cited by 22
Li, R., Yuan, M., Yu, S., Fu, W., Wu, Y., Ling, S., Sun, J., & Chen, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105413 · Cited by 25
Ebraheem, M. S., Alzahrani, I., Crowther, M. A., Rochwerg, B. N., & Almakadi, M. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14949 · Cited by 22
Tarango, C., Schulman, S., Betensky, M., & Goldenberg, N. A. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1407241 · Cited by 21
“These studies suggest that aspirin after standard-duration anticoagulation can reduce the risk of VTE recurrence in adults with unprovoked VTE [31].”
BackgroundPompilio, G., Integlia, D., Raffetto, J. D., & Palareti, G. (2020) · TH Open · doi:10.1055/s-0040-1709731 · Cited by 21
Ghule, P., Panich, J., & Malone, D. C. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae010 · Cited by 20
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin
Prandoni, P., Lensing, A. W. A., Prins, M. H., Gebel, M., Pap, A. F., Homering, M., Bauersachs, R. M., Beyer‐Westendorf, J., Bounameaux, H., Cohen, A. T., et al. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.06.009 · Cited by 14
Li, A., Khatib, R., Lopes, L. C., Aloweni, F. B. A. B., Lu, L., He, Q., Wu, J., Zhang, P., Tang, Y., Pavalagantharajah, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015371 · Cited by 14
[Studies on chemical constituents of root of Cichorium intybus].
He, Y., Guo, Y.-J., & Gao, Y.-Y. (2002) · PubMed · Cited by 14
Wang, M. K., Baskaran, G., Razeghi, G., Ma, R., Park, L., Tannu, M., Devereaux, P. J., McIntyre, W. F., Healey, J. S., Shoamanesh, A., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02132 · Cited by 8
“By comparison, aspirin is usually less preferred because of its reduced ef fi cacy (30).”
Zekery-Saad, S. A., Lewin, A. R., Pham, M., Sylvester, K. W., Fanikos, J. R., Goldhaber, S. Z., & Connors, J. M. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02207-3 · Cited by 8
Li, D., Liu, Y., Song, Y. H., & Wen, A. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2026002 · Cited by 6
“Our study indicated that all anticoagulant treatments could reduce the risk of recurrent VTE, which is consistent with previous studies [40,41].”
BackgroundResultMichaud, I., & Landry, P. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000888 · Cited by 6
Михайлович, М. С., Grishin, S. V., & Артемова, А. С. (2023) · The Clinician · doi:10.17650/1818-8338-2023-17-2-k688 · Cited by 3
Бурлева, Е. П., & Kremenevskiy, O. M. (2019) · Journal of Venous Disorders · doi:10.17116/flebo20191301142 · Cited by 3
Quintanar, T., Font, C., Gallardo, E., Barba, R., Obispo, B., & Díaz‐Pedroche, C. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02477-6 · Cited by 3
Saudi Clinical Practice Guidelines for management of diabetic kidney disease in adults
Almatham, K. I., Almudaiheem, H., Alhazzani, W. A., Alotaibi, H. F., Alobaili, S. S., Tawhari, M. H., Alsifri, S. N., Albakr, R. B., Alomi, M., Alenzi, K. A. O., et al. (2025) · Saudi Medical Journal · doi:10.15537/smj.2025.46.10.20250326 · Cited by 3
Sane, M., Laukkanen, J. A., Granér, M., Piilonen, A. K., Raade, M., Harjola, V., & Mustonen, P. E. (2018) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12867 · Cited by 3
Kapur, V., & Goyal, S. M. (2023) · Wiley eBooks · doi:10.1002/9781119467779.ch14 · Cited by 2
Pulmonary embolism due to an indefinite plug: 5-year follow-up
Çil, E., & Şahin, K. E. (2022) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivac202 · Cited by 2
Hashimoto, H., Imai, S., Kiyomi, A., & Sugiura, M. (2022) · Thrombosis Update · doi:10.1016/j.tru.2022.100113 · Cited by 1
Medical Therapy for Chronic Thromboembolic Pulmonary Hypertension
Satoh, T. (2017) · Springer eBooks · doi:10.1007/978-981-287-840-3_14 · Cited by 1
Ozaal, A. M. O. M., & Fernando, T. (2022) · SAGE Open Medical Case Reports · doi:10.1177/2050313x221089121 · Cited by 1
The Aftermath of Pulmonary Embolism: Are Residual Thrombi Clinically Significant?
Pocienė, I., & Danila, E. (2025) · Diagnostics · doi:10.3390/diagnostics15111348 · Cited by 1
“However, this benefit disappears once treatment is discontinued [51,52].”
Risk factors for deep venous thrombosis in patients with acute stroke
Nishihira, T., Takekawa, H., Okamura, M., Okabe, R., Suzuki, K., Iwasaki, A., Suzuki, A., Tsukahara, Y., & Hirata, K. (2016) · Neurosonology · doi:10.2301/neurosonology.29.28
Böhner, H. (2016) · Gefässchirurgie · doi:10.1007/s00772-016-0214-y
“Ob diese Indikation dauerhaft erhalten bleibt, obwohl dosisreduzierte direkte orale Antikoagulanzien effektiver und mit geringer Blutungsneigung einsetzbar sind [6], bleibt abzuwarten.”
BackgroundControversias sobre la enfermedad tromboembólica venosa no provocada en ancianos
Ríos-Prego, M., NÚÑEZ-FERNÁNDEZ, M. J., & Monréal, M. (2016) · Galicia Clínica · doi:10.22546/38/937
Samuel, R., Dixon, A. M., Kretschmar, P. K., Fletcher, M., & Warrier, R. P. (2019) · Clinical Pediatrics · doi:10.1177/0009922819881208
“A meta-analysis comparing vitamin K antagonists, direct-acting oral anticoagulants (DOACs), and aspirin in DVT prevention concluded aspirin to be the least efficacious of the three but the most favorable side effect profile.(6) With the”
BackgroundOxidative Stress as a Thrombophilic Factor in Behçet Syndrome
Emmi, G., Becatti, M., Bettiol, A., Fiorillo, C., & Prisco, D. (2019) · Springer eBooks · doi:10.1007/978-3-030-24131-5_14 · Cited by 1
Innovation and standardization of near-patient platelet function assays
Sang, Y. (2020) · Research Publications (Maastricht University) · doi:10.26481/dis.20201111ys
Commonly Prescribed Medications that Affect Clotting: A Comprehensive Overview
Shelvan, A., Spence, A. L., Parsiola, A. L., Anandi, P., Siddaiah, H. B., Latimer, D. R., Saus, J. A., Prabhakar, A., Core, D. E., Cornett, E. M., et al. (2021) · Springer eBooks · doi:10.1007/978-3-030-59295-0_19
Nakai, Y., & Sumise, Y. (2024) · The Japanese Journal of Phlebology · doi:10.7134/phlebol.23-35
Antiplatelet Therapy for Venous Thromboembolism
Poénou, G., & Heestermans, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-96360-5_13
Watfa, A., Younis, A., Winnard-Brewer, A., Greenlee, K. M., Ferrin, J., Varma, N., Myers, J., Wotring, V. E., & Mayuga, K. A. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100724
“For individuals with a first unprovoked DVT, multiple meta-analyses show that extended oral anticoagulant therapy significantly lowers the rate of recurrent VTE compared with discontinuation [49,50].”
Mantoo, M. R., Mantoo, D. S. R., Majeed, M. W., Kulkarni, A., Lone, H. P., Mansoor, M., & Roy, A. (2026) · Romanian Journal of Cardiology · doi:10.2478/rjc-2026-0014
Metadata
- Authors
- Marik, P. E., & Cavallazzi, R.
- Affiliations
- Eastern Virginia Medical School (US)
- University of Louisville (US)
- Corresponding author
- Marik, Paul E.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-11-20
- Volume
- 10
- Issue
- 11
- Pages
- e0143252
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4654552
- OpenAlex
- W2180178994
- Cited by
- 53
- References
- 43
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 10 · 2019: 4 · 2018: 7 · 2017: 5 · 2016: 7
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- long-term anticoagulation, venous thromboembolism, deep vein thrombosis, pulmonary embolism, aspirin, direct oral anticoagulants, vitamin K antagonists, secondary prevention, recurrent venous thromboembolism, major bleeding, mortality, unprovoked thrombosis, clinical equipoise
- MeSH terms
- Anticoagulants, Aspirin, Data Collection, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Recurrence, Risk Factors, Sex Factors, Thromboembolism, Vitamin K, Warfarin, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.